405 related articles for article (PubMed ID: 18214064)
21. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L
Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151
[TBL] [Abstract][Full Text] [Related]
22. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
23. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
24. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
Pisters KM; Evans WK; Azzoli CG; Kris MG; Smith CA; Desch CE; Somerfield MR; Brouwers MC; Darling G; Ellis PM; Gaspar LE; Pass HI; Spigel DR; Strawn JR; Ung YC; Shepherd FA; ;
J Clin Oncol; 2007 Dec; 25(34):5506-18. PubMed ID: 17954710
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
Yilmaz A; Ernam D; Unsal E; Demirag F; Atikcan S; Taştepe I
Arch Med Res; 2007 Oct; 38(7):764-8. PubMed ID: 17845896
[TBL] [Abstract][Full Text] [Related]
26. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
Dai CH; Li J; Shi SB; Yu LC; Ge LP; Chen P
Jpn J Clin Oncol; 2010 Apr; 40(4):327-35. PubMed ID: 20056675
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
Tan DF; Li Q; Rammath N; Beck A; Wiseman S; Anderson T; al-Salameh A; Brooks J; Bepler G
Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
[TBL] [Abstract][Full Text] [Related]
30. [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection].
Wei WD; Wen ZS; Su XD; Lin P; Rong TH; Chen LK
Ai Zheng; 2007 Nov; 26(11):1231-6. PubMed ID: 17991324
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of polysialic acid expression in resected non-small cell lung cancer.
Tanaka F; Otake Y; Nakagawa T; Kawano Y; Miyahara R; Li M; Yanagihara K; Inui K; Oyanagi H; Yamada T; Nakayama J; Fujimoto I; Ikenaka K; Wada H
Cancer Res; 2001 Feb; 61(4):1666-70. PubMed ID: 11245481
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy.
Hanaoka N; Tanaka F; Wada H
Thorac Cardiovasc Surg; 2002 Dec; 50(6):355-9. PubMed ID: 12457313
[TBL] [Abstract][Full Text] [Related]
33. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer.
Dworakowska D; Jassem E; Jassem J; Boltze C; Wiedorn KH; Dworakowski R; Skokowski J; Jaśkiewicz K; Czestochowska E
Acta Oncol; 2005; 44(1):75-9. PubMed ID: 15848909
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
35. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.
Hsu NY; Ho HC; Chow KC; Lin TY; Shih CS; Wang LS; Tsai CM
Cancer Res; 2001 Mar; 61(6):2727-31. PubMed ID: 11289154
[TBL] [Abstract][Full Text] [Related]
37. Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer.
Chen CY; Hsu CP; Hsu NY; Shih CS; Lin TY; Chow KC
Oncol Rep; 2002; 9(3):515-9. PubMed ID: 11956619
[TBL] [Abstract][Full Text] [Related]
38. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
39. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures.
Fan J; Wang L; Jiang GN; He WX; Ding JA
Lung Cancer; 2008 Jul; 61(1):91-6. PubMed ID: 18192073
[TBL] [Abstract][Full Text] [Related]
40. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
